NPORT-EX 2 NPORT_2783937281178373.htm iShares Genomics Immunology and Healthcare ETF

Schedule of Investments (unaudited) 

October 31, 2020

   

iShares® Genomics Immunology and Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

    
Denmark — 4.3%            

Genmab A/S(a)

    20,328     $ 6,771,282  
   

 

 

  
France — 3.3%            

Sanofi

     58,465       5,269,123  
   

 

 

  
Germany — 8.2%            

BioNTech SE, ADR(a)(b)

    11,344       968,324  

Merck KGaA

     49,476       7,327,921  

MorphoSys AG(a)

    45,948       4,686,430  
   

 

 

  
      12,982,675  
Japan — 8.1%            

Kyowa Kirin Co. Ltd.

     222,100       5,502,573  

Sumitomo Dainippon Pharma Co. Ltd.

     201,600       2,356,564  

Takeda Pharmaceutical Co. Ltd.

     160,100       4,960,436  
   

 

 

  
          12,819,573  
Netherlands — 1.3%            

uniQure NV(a)

    51,072       2,064,841  
   

 

 

  
Switzerland — 3.9%            

CRISPR Therapeutics AG(a)

    67,284       6,178,017  
   

 

 

  
United Kingdom — 0.3%            

Orchard Therapeutics PLC(a)(b)

    126,756       512,094  
   

 

 

  
United States — 70.4%            

Adverum Biotechnologies Inc.(a)

    107,352       1,171,210  

Agenus Inc.(a)

    209,496       773,040  

Allogene Therapeutics Inc.(a)

    85,260       2,892,019  

AnaptysBio Inc.(a)

    37,800       1,113,588  

Bluebird Bio Inc.(a)(b)

    83,076       4,295,860  

Bridgebio Pharma Inc.(a)

    110,880       4,255,574  

Constellation Pharmaceuticals Inc.(a)

    38,808       761,413  

CytomX Therapeutics Inc.(a)

    67,452       446,532  

Editas Medicine Inc.(a)

    82,404       2,549,580  

Exelixis Inc.(a)

    263,592       5,398,364  

Fate Therapeutics Inc.(a)

    113,736       5,049,878  

FibroGen Inc.(a)

    123,816       4,752,058  

Gilead Sciences Inc.

     76,776       4,464,524  

Inovio Pharmaceuticals Inc.(a)(b)

    234,108       2,305,964  

Intellia Therapeutics Inc.(a)(b)

    67,284       1,610,779  

Invitae Corp.(a)

    182,280       7,147,199  

Iovance Biotherapeutics Inc.(a)(b)

    187,740       6,698,563  

Karyopharm Therapeutics Inc.(a)(b)

    97,020       1,437,836  

Kura Oncology Inc.(a)

    75,516       2,359,875  
Security   Shares     Value  
United States (continued)            

Ligand Pharmaceuticals Inc.(a)

    23,546     $ 1,941,368  

MacroGenics Inc.(a)

    67,620       1,312,504  

Mirati Therapeutics Inc.(a)(b)

    60,732       13,187,347  

Moderna Inc.(a)

    101,304       6,834,981  

NanoString Technologies Inc.(a)

    56,952       2,087,291  

Precision BioSciences Inc.(a)

    53,508       337,635  

Provention Bio Inc.(a)

    56,028       664,492  

Regeneron Pharmaceuticals Inc.(a)

    9,870       5,364,937  

Sangamo Therapeutics Inc.(a)(b)

    168,252       1,739,726  

Sarepta Therapeutics Inc.(a)(b)

    39,816       5,411,393  

Seagen Inc.(a)

    39,732       6,627,298  

Translate Bio Inc.(a)

    64,120       822,660  

Twist Bioscience Corp.(a)

    46,200       3,540,768  

Vir Biotechnology Inc.(a)

    48,720       1,531,757  

Voyager Therapeutics Inc.(a)

    36,624       389,313  

ZIOPHARM Oncology Inc.(a)(b)

    305,172       637,810  
   

 

 

  
          111,915,136  
   

 

 

  

Total Common Stocks — 99.8%
(Cost: $153,755,081)

 

     158,512,741  
   

 

 

  

Short-Term Investments

    

Money Market Funds — 4.4%

    

BlackRock Cash Funds: Institutional, SL Agency Shares, 0.20%(c)(d)(e)

    6,913,598       6,918,438  

BlackRock Cash Funds: Treasury, SL Agency Shares, 0.04%(c)(d)

    124,000       124,000  
   

 

 

  
      7,042,438  
   

 

 

  

Total Short-Term Investments — 4.4%
(Cost: $7,041,750)

 

     7,042,438  
   

 

 

  

Total Investments in Securities — 104.2%
(Cost: $160,796,831)

 

     165,555,179  
Other Assets, Less Liabilities — (4.2)%         (6,724,125)  
   

 

 

  

Net Assets — 100.0%

     $ 158,831,054  
   

 

 

  

 

(a) 

Non-income producing security.

(b) 

All or a portion of this security is on loan.

(c) 

Affiliate of the Fund.

(d) 

Annualized 7-day yield as of period-end.

(e) 

All or a portion of this security was purchased with cash collateral received from loaned securities.

 

 

 

    

   1

Schedule of Investments (unaudited) (continued)

October 31, 2020

   

iShares® Genomics Immunology and Healthcare ETF

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

 

  
Affiliated Issuer  

Value at

07/31/20

   

Purchases

at Cost

   

Proceeds

from Sales

   

Net Realized

Gain (Loss)

   

Change in

Unrealized

Appreciation

(Depreciation)

    

Value at

10/31/20

   

Shares

Held at

10/31/20

    Income    

Capital

Gain
Distributions

from

Underlying

Funds

 

 

  

BlackRock Cash Funds: Institutional, SL Agency
Shares

   $ 13,668,970     $ —     $ (6,747,165 )(a)    $ (3,214 )    $ (153 )    $ 6,918,438       6,913,598     $ 94,575 (b)    $ —  

BlackRock Cash Funds: Treasury, SL Agency
Shares

     124,000       0 (a)       —       —       —       124,000       124,000       25       —  
       

 

 

    

 

 

    

 

 

      

 

 

    

 

 

  
        $ (3,214 )    $ (153 )    $ 7,042,438       $ 94,600     $ —  
       

 

 

    

 

 

    

 

 

      

 

 

    

 

 

  

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Fair Value Measurements

Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.

The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of October 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.

 

 

  
     Level 1        Level 2        Level 3        Total  

 

  

Investments

                  

Assets

                  

Common Stocks

    $ 158,512,741        $ —        $ —        $ 158,512,741  

Money Market Funds

      7,042,438                  —                  —          7,042,438  
  

 

 

       

 

 

       

 

 

       

 

 

  
   $ 165,555,179        $ —        $ —        $ 165,555,179  
  

 

 

       

 

 

       

 

 

       

 

 

  

 

Portfolio Abbreviations - Equity
ADR    American Depositary Receipt

 

 

2